Viewing Study NCT01522469


Ignite Creation Date: 2025-12-24 @ 10:54 PM
Ignite Modification Date: 2025-12-25 @ 8:22 PM
Study NCT ID: NCT01522469
Status: COMPLETED
Last Update Posted: 2024-01-30
First Post: 2012-01-30
Is NOT Gene Therapy: False
Has Adverse Events: True

Brief Title: Phase II Study of Crenolanib in Subjects With Relapsed/Refractory AML With FLT3 Activating Mutations
Sponsor: Arog Pharmaceuticals, Inc.
Organization: